MRNA Modernadata gap · 63% coveragelimited data
Health Care · Biotechnology · close $218.01 (2026-10-16) · latest quarter in EDGAR: 2026-06-30
Moderna (MRNA) has a ThetaGrade House Rating of 12/100 (grade F), ranking #48 of 150 in Health Care. Its strongest pillars are analyst sentiment (50) and balance sheet (27); its weakest is growth (2). Data gap: 4 factors without usable data, so 63% of the method weight is covered. TTM revenue growth is -27.6% and operating margin -149.0%.
Data as of .
Data gap
No usable data for: EPS growth YoY (TTM), 4Q gross-margin change, Net debt / EBITDA, P/E (inverted). Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 63% of the full method weight is backed by data.
Analyst sentiment
weight 7.5% · 50| Consensus score (1–5) (3.8%) | derived | 0 |
| 90-day net rating shift (3.8%) | derived | 100 |
Growth
weight 30.83% · 2| Revenue growth YoY (TTM) (20.5%) | -27.6% | 2 |
| EPS growth YoY (TTM) (0.0%)data gap | — | — |
| Revenue acceleration (10.3%) | -258.1% | 2 |
Profitability
weight 18.5% · 5| Operating margin (18.5%) | -149.0% | 5 |
| 4Q gross-margin change (0.0%)data gap | — | — |
Balance sheet
weight 18.5% · 27| Net debt / EBITDA (0.0%)data gap | — | — |
| Current ratio (10.6%) | 2.29 | 46 |
| Interest coverage (7.9%) | -332.00× | 2 |
Cash flow
weight 12.33% · 12| FCF margin (6.2%) | -106.2% | 8 |
| FCF yield (6.2%) | -2.4% | 16 |
Valuation
weight 12.33% · 5| P/E (inverted) (0.0%)data gap | — | — |
| EV/Sales (inverted) (12.3%) | 38.56× | 5 |
Technicals (EOD)
| RSI(14) | 61.7 |
| EMA 9 / 21 | 215.24 / 197.77 |
| 200-day SMA | 77.40 |
| Volume vs 20d avg | 1.17× |
| 20-day return | 37.9% |
Exit-rule monitor
- EXITRating break: House Rating below 60
- EXITFundamental miss: revenue growth negative YoY
- EXITBalance-sheet stress: negative free cash flow (latest FY)
Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Operating income: OperatingIncomeLoss · Interest expense: InterestPaidNet · D&A: DepreciationDepletionAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close.
Get rating changes like MRNA's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is MRNA's House Rating?
- MRNA scores 12 out of 100 (grade F) as of 2026-10-16, ranking #48 of 150 Health Care stocks we cover.
- What do analysts say about MRNA?
- ThetaGrade's analyst-sentiment pillar for MRNA scores 50/100 against its sector peers, which we read as mixed. This is our own derived score; we do not republish individual analyst ratings, counts or targets.
- When does MRNA report earnings next?
- MRNA's next earnings report is estimated for about 2026-11-05 (window 2026-11-02 to 2026-11-08), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.
- Is MRNA a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology